Key result
Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibited intermediate clinical characteristics, cardiac event rates, and all-cause mortality compared to HFrEF and HFpEF.
Why the study?
Heart failure with mid-range ejection fraction (HFmrEF; LVEF 40-49%) had recently been focused upon, but its clinical features and outcomes had not yet been fully examined.
Observational (n=2,103)
No
Answers are grounded in this paper and cite their sources.
Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibit distinct clinical characteristics and an intermediate prognosis compared to those with HFrEF and HFpEF.
Left ventricular ejection fraction (LVEF) is used in the diagnosis, characterization, prognosis, patient triage, and treatment selection of heart failure.1,–3 Heart failure with reduced ejection fraction (HFrEF; LVEF <40%) is well characterized and established for evidence-based therapy, whereas heart failure with preserved ejection fraction (HFpEF; LVEF ≥50%) is a common and complex syndrome without evidence-based therapy.1,2 Heart failure with mid-range ejection fraction (HFmrEF; LVEF 40–49%) has recently been focused upon; however, the clinical features and outcome have not yet been fully examined.4,,,–8 This was a prospective observational study of decompensated heart failure patients who were discharged from Fukushima Medical University Hospital between 2010 and 2016. The diagnosis and management of decompensated heart failure was made by experienced cardiologists based on the heart failureguidelines.9 We divided the patients into three groups based on their LVEF at hospital discharge, which was assessed via echocardiography: HFrEF (LVEF < 40%, n = 629), HFmrEF (LVEF 40–49%, n = 313) and HFpEF (LVEF ≥ 50%, n = 1161). We compared the clinical features, laboratory data, parameters of electrocardiogram, echocardiography,10 cardiopulmonary exercise test,3 right-heart catheterizations10 and post-discharge prognosis. The patients were followed up until 2018 for cardiac events and all-cause death. Cardiac events were defined as worsened heart failure and cardiac death. Cardiac death was classified by independent experienced cardiologists as death from worsened heart failure, ventricular fibrillation documented by electrocardiogram or implantable devices, or acute coronary syndrome. The study protocol was approved by the ethical committee of Fukushima Medical University (No. 823), the investigation conformed to the principles outlined in the Declaration of Helsinki. Echocardiography was performed blindly by experienced echocardiographers using standard techniques.10 The echocardiographic parameters investigated included left ventricular diastolic dimension (LVDd), left ventricular systolic dimension (LVDs), LVEF, inferior vena cava diameter (IVC), tricuspid regurgitation pressure gradient (TR-PG) and right ventricular fractional area change (RV-FAC).10 The LVEF was calculated using Simpson’s method in a four-chamber view.10 The patients underwent cardiopulmonary exercise test (n = 645)3 and right-heart catheterizations (n = 353)10 before discharge by attending physicians. Peak VO2 and ventilatory response to exercise (slope of the relationship between ventilation and carbon dioxide production (VE/VCO2 slope)) was calculated as previously reported.3 The clinical characteristics of patients are presented in Table 1. Age was higher in both the HFmrEF and HFpEF groups than in the HFrEF group. Prevalence of male gender, diabetes, dyslipidemia and sleep-disordered breathing were highest in the HFrEF group. The HFmrEF group showed intermediate prevalence of above characteristics between the HFrEF and HFpEF groups. In contrast, prevalence of coronary artery disease, hypertension, chronic kidney disease and peripheral artery disease was highest in HFmrEF groups. LVEF, TR-PG, RV-FAC and cardiac index increased from the HFrEF group to the HFmrEF group to the HFpEF groups, whereas B-type natriuretic peptide, LVDd, LVDs, IVC, QRS duration, QTc and pulmonary artery wedge pressure decreased from the HFrEF group to the HFmrEF group to the HFpEF group (p < 0.01). In contrast, other parameters, including PQ, QT, peak VO2 and VE/VCO2 slope, did not significantly differ among the groups. Comparisons of clinical features between the ejection fraction groups (N = 2103). p < 0.05 and **p < 0.01 vs. HFrEF group, †p < 0.05 and ††p < 0.01 vs. HFmrEF group. Data are presented as median (interquartile range). HFrEF; heart failure with reduced ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction; ANOVA: analysis of variance; BNP: B-type natriuretic peptide; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; PAD: peripheral artery disease; RAS: renin–angiotensin–aldosterone system; ICD: implantable cardiac defibrillator; CRT: cardiac resynchronization therapy; CLBBB: complete left bundle branch block; LVEF: left ventricular ejection fraction; LVDd: left ventricular end diastolic dimension; LVDs: left ventricular end systolic dimension; IVC: inferior vena cava diameter; TR-PG: tricuspid regurgitation pressure gradient; RV-FAC: right ventricular fractional area change; Peak VO2: breath-by-breath oxygen consumption; VE/VCO2 slope: slope of the relationship between ventilation and carbon dioxide production; PAWP: pulmonary artery wedge pressure Comparisons of clinical features between the ejection fraction groups (N = 2103). p < 0.05 and **p < 0.01 vs. HFrEF group, †p < 0.05 and ††p < 0.01 vs. HFmrEF group. Data are presented as median (interquartile range). HFrEF; heart failure with reduced ejection fraction; HFmrEF: heart failure with mid-range ejection fraction; HFpEF: heart failure with preserved ejection fraction; ANOVA: analysis of variance; BNP: B-type natriuretic peptide; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; PAD: peripheral artery disease; RAS: renin–angiotensin–aldosterone system; ICD: implantable cardiac defibrillator; CRT: cardiac resynchronization therapy; CLBBB: complete left bundle branch block; LVEF: left ventricular ejection fraction; LVDd: left ventricular end diastolic dimension; LVDs: left ventricular end systolic dimension; IVC: inferior vena cava diameter; TR-PG: tricuspid regurgitation pressure gradient; RV-FAC: right ventricular fractional area change; Peak VO2: breath-by-breath oxygen consumption; VE/VCO2 slope: slope of the relationship between ventilation and carbon dioxide production; PAWP: pulmonary artery wedge pressure Rates of cardiac events and all-cause mortality in the left ventricular ejection fraction groups (N = 2103). Kaplan–Meier analysis for cardiac event rate and all-cause mortality in the heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) groups. Rates of cardiac events and all-cause mortality in the left ventricular ejection fraction groups (N = 2103). Kaplan–Meier analysis for cardiac event rate and all-cause mortality in the heart failure with reduced ejection fraction (HFrEF), heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) groups. We focused on the HFmrEF patients, who accounted for 14.9% of the decompensated heart failure patients, and the HFmrEF group had cardiac events and all-cause mortality at intermediate rates between the HFrEF and HFpEF groups in the present study. Concordant with our data, recent meta-analyses have reported that the prevalence of HFmrEF was 8.2–38.3%, HFrEF was 9.6–68.2% and HFpEF was 9.5–61.9%, and that HFmrEF had a lower all-cause mortality than HFrEF (relative risk 0.9, 95% confidence interval 0.85–0.94).6 Compared with previous studies,4,,,–8 this is the first study to show not only prognosis but also comprehensive clinical characteristics including co-morbidities, parameters of electrocardiogram, cardiopulmonary exercise testing and right-heart catheterizations in HFmrEF as compared with HFrEF and HFpEF. The present study has several limitations. First, as a prospective cohort study of a single center with a relatively small number of patients, the present results may not be representative of the general population. Second, the present study included only variables during hospitalization for decompensated heart failure, and we did not take into consideration changes in medical parameters or treatments after discharge. Third, performing cardiopulmonary exercise test or right-heart catheterization was determined by attending physicians, and there might be selection bias. Therefore, the present results should be viewed as preliminary, and further studies with larger populations are needed. Patients with HFmrEF had several intermediate clinical characteristics between the HFrEF and HFpEF groups.
No takes yet. Share an insight, caveat, or question.
Yoshihisa et al. (2019) conducted an observational in Decompensated heart failure (n=2,103). Heart failure with mid-range ejection fraction (HFmrEF) vs. Heart failure with reduced (HFrEF) and preserved (HFpEF) ejection fraction was evaluated on Cardiac events (worsened heart failure and cardiac death) and all-cause death. Patients with heart failure with mid-range ejection fraction (HFmrEF) exhibited intermediate clinical characteristics, cardiac event rates, and all-cause mortality compared to HFrEF and HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: